Literature DB >> 28480065

Hepatocellular carcinoma (HCC): beyond sorafenib-chemotherapy.

Dae Won Kim1, Chetasi Talati1, Richard Kim1.   

Abstract

Hepatocellular carcinoma (HCC) is the most common primary liver cancer with poor prognosis. The incidence of HCC and HCC-related deaths have increased over the last several decades. However, the treatment options for advanced HCC are very limited. Sorafenib remains the only drug approved for systemic treatment for advanced HCC. However, prior to sorafenib era conventional cytotoxic chemotherapies have been studied in advanced HCC. In this review, clinical studies of systemic chemotherapy for advanced HCC will be summarized and discussed.

Entities:  

Keywords:  Advanced HCC; chemotherapy

Year:  2017        PMID： 28480065      PMCID： PMC5401857          DOI： 10.21037/jgo.2016.09.07

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN： 2078-6891


  75 in total

1.  Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells.

Authors:  Y Lavie; H t Cao; A Volner; A Lucci; T Y Han; V Geffen; A E Giuliano; M C Cabot
Journal:  J Biol Chem       Date:  1997-01-17       Impact factor: 5.157

2.  Chemotherapy studies in primary liver cancer: a prospective randomized clinical trial.

Authors:  G Falkson; C G Moertel; P Lavin; F J Pretorius; P P Carbone
Journal:  Cancer       Date:  1978-11       Impact factor: 6.860

3.  Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: a multicenter phase II study with dose adjustment according to baseline serum bilirubin level.

Authors:  Valérie Boige; Julien Taïeb; Mohamed Hebbar; David Malka; Thierry Debaere; Laurent Hannoun; Emmanuelle Magherini; Dominique Mignard; Thierry Poynard; Michel Ducreux
Journal:  Eur J Cancer       Date:  2006-01-20       Impact factor: 9.162

4.  Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.

Authors:  Ghassan K Abou-Alfa; Philip Johnson; Jennifer J Knox; Marinela Capanu; Irina Davidenko; Juan Lacava; Thomas Leung; Bolorsukh Gansukh; Leonard B Saltz
Journal:  JAMA       Date:  2010-11-17       Impact factor: 56.272

5.  Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma.

Authors:  Abby B Siegel; Emil I Cohen; Allyson Ocean; Deborah Lehrer; Alec Goldenberg; Jennifer J Knox; Helen Chen; Sean Clark-Garvey; Alan Weinberg; John Mandeli; Paul Christos; Madhu Mazumdar; Elizabeta Popa; Robert S Brown; Shahin Rafii; Jonathan D Schwartz
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

6.  A phase II study of gemcitabine and cisplatin in patients with advanced hepatocellular carcinoma.

Authors:  P M Parikh; J Fuloria; G Babu; D C Doval; B S Awasthy; V R Pai; P S Prabhakaran; A B Benson
Journal:  Trop Gastroenterol       Date:  2005 Jul-Sep

Review 7.  Systemic therapy of hepatocellular carcinoma: are we making progress?

Authors:  Patricia Roxburgh; T R Jeffry Evans
Journal:  Adv Ther       Date:  2008-11       Impact factor: 3.845

8.  Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients.

Authors:  A Castells; J Bruix; C Brú; C Ayuso; M Roca; L Boix; R Vilana; J Rodés
Journal:  Gastroenterology       Date:  1995-09       Impact factor: 22.682

9.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

Review 10.  Role of estrogen in hepatocellular carcinoma: is inflammation the key?

Authors:  Liang Shi; Yili Feng; Hui Lin; Rui Ma; Xiujun Cai
Journal:  J Transl Med       Date:  2014-04-08       Impact factor: 5.531
View more
  87 in total

1.  Application of Trifluoroacetic Acid as a Theranostic Agent for Chemical Ablation of Solid Tissue.

Authors:  Samuel A Einstein; Emily A Thompson; Chunxiao Guo; Elizabeth M Whitley; James A Bankson; Erik N K Cressman
Journal:  J Vasc Interv Radiol       Date:  2019-09-16       Impact factor: 3.464

2.  Identification of Immune-Related Markers in Hepatocellular Carcinoma Based on Gene Co-expression Network.

Authors:  Guogang Li; Yang Tian; Zhenzhen Gao; Xi Ma; Chaojie Ren
Journal:  Biochem Genet       Date:  2022-05-28       Impact factor: 1.890

3.  EV-T synergizes with AZD5582 to overcome TRAIL resistance through concomitant suppression of cFLIP, MCL-1, and IAPs in hepatocarcinoma.

Authors:  Kui Su; Qian Yuan; Huan Hou; Changhong Ke; Chaohong Huang; Shuyi Li; Jianwu Sun; Xin Yuan; Yue Lin; Yiqing Chen; Huijuan Xin; Xiaoping Liang; Zhiyun Du; Zhengqiang Yuan
Journal:  J Mol Med (Berl)       Date:  2022-03-05       Impact factor: 4.599

4.  Interleukin-35 has a tumor-promoting role in hepatocellular carcinoma.

Authors:  X Liu; H Ren; H Guo; W Wang; N Zhao
Journal:  Clin Exp Immunol       Date:  2020-10-26       Impact factor: 4.330

5.  CircC16orf62 promotes hepatocellular carcinoma progression through the miR-138-5p/PTK2/AKT axis.

Authors:  Shuai Zhang; Yuan Lu; Hong-Yu Jiang; Zhi-Mei Cheng; Zi-Jing Wei; Yun-Hao Wei; Ting Liu; Bai-Juan Xia; Xu-Ya Zhao; Yu Huang; Xun Zou; Rong Liu; Shi Zhou
Journal:  Cell Death Dis       Date:  2021-06-09       Impact factor: 8.469

6.  The novel immune-related genes predict the prognosis of patients with hepatocellular carcinoma.

Authors:  Lunxu Li; Shilin Xia; Xueying Shi; Xu Chen; Dong Shang
Journal:  Sci Rep       Date:  2021-05-21       Impact factor: 4.379

7.  Liposome-Coated Arsenic-Manganese Complex for Magnetic Resonance Imaging-Guided Synergistic Therapy Against Carcinoma.

Authors:  Zhexiu Jin; Xue Yi; Jingjing Yang; Meili Zhou; Peifu Wu; Gen Yan
Journal:  Int J Nanomedicine       Date:  2021-06-01

Review 8.  Diet-Regulating Microbiota and Host Immune System in Liver Disease.

Authors:  Jung A Eom; Goo Hyun Kwon; Na Yeon Kim; Eun Ju Park; Sung Min Won; Jin Ju Jeong; Ganesan Raja; Haripriya Gupta; Yoseph Asmelash Gebru; Satyapriya Sharma; Ye Rin Choi; Hyeong Seop Kim; Sang Jun Yoon; Ji Ye Hyun; Min Kyo Jeong; Hee Jin Park; Byeong Hyun Min; Mi Ran Choi; Dong Joon Kim; Ki Tae Suk
Journal:  Int J Mol Sci       Date:  2021-06-13       Impact factor: 5.923

9.  Study of the G Protein Nucleolar 2 Value in Liver Hepatocellular Carcinoma Treatment and Prognosis.

Authors:  Yiwei Dong; Qianqian Cai; Lisheng Fu; Haojie Liu; Mingzhe Ma; Xingzhong Wu
Journal:  Biomed Res Int       Date:  2021-07-19       Impact factor: 3.411

10.  Donafenib treatment for hepatocellular carcinoma: A case report.

Authors:  Qiaoqi Li; Hong Zhu
Journal:  Medicine (Baltimore)       Date:  2021-06-25       Impact factor: 1.889
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.